Archive | March, 2022

Seeking Capital or Licensing Deal? Here’s Why Digital RESI March is Important

17 Mar

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series; Caitlin Dolegowski, Marketing Specialist, LSN

Finding the right capital or channel partner is a numbers game, which means that you need to get in front of potential partners regularly. This is why the Redefining Early Stage Investments (RESI) conference takes place five times each year. You never know when a connection will surface that leads to a partnership, so you must be in the game to make it happen.

RESI is different from other partnering conferences in that it does real-time dynamic matching. The team at Life Science Nation (LSN) pre-loads investor profiles from mandates collected and stored in the LSN Investor Database. That is a big deal because (at most partnering events) investors typically have very light or even empty profiles. Because LSN has all the investors and licensing partners’ updated profiles in our database, this makes a huge difference in the quality of RESI meetings.

LSN can match based on fit, which in turn means great meetings can happen as both parties are looking for each other. Instead of booking a meeting and realizing there is no fit (which is common at other partnering conferences), RESI is unique because:

  1. There is the option to filter partners by capital investment and licensing mandates and match on stage of development and product.
  2. Most investor and licensing partner profiles are uploaded from our curated partnering database, so the user does not need to update their profile, unless they choose to, which has been a game-changer.
  3. Scientist-entrepreneurs and fundraising CEOs can opt to upgrade to a premier profile as part of RESI Premier Partnering to access deeper detailed investor mandates, which also include valuable contact information.

Another facet of Digital RESI March is the variety of panels focused on educating the entrepreneur on key components to partnering in the life science and health care early-stage arena. Hear straight from relevant investors and industry experts. These panels are created with the same intent and spirit of our partnering platform – To bring quality content with the early-stage life science entrepreneur in mind. Hear best practices, lessons learned, and valuable insight from our panelists. These panels are available to attendees live or their recordings are available on the meeting platform. Check out the panelists presenting at Digital RESI March below.

Tuesday, March 22, 11 AM EDT

Early-Stage Therapeutics

Bringing the Newest Therapies to the Clinic

Yaniv Sneor
Founder
Mid Atlantic Bio Angels
(Moderator)		 Cynthia Cai, PhD, MBA
Venture Partner
Viva BioInnovator		 Catello Somma, MBA
Associate
;TVM Capital Life Science
Scott Weiner
Partner, Amzak Health		 Sa’ar Yaniv
Director, Business Development, Fortress Biotech

Tuesday, March 22, 2 PM EDT

Digital Health & Wellness

Silver-Tech Focusing on Preventative Care

Brenda Hogan, MBA
Senior Investment Manager
Ontario Capital Growth Corporation (OCGC)
(Moderator)		 Moshe Bellows, JD
General Partner
Maccabee Ventures		 Seemant Jauhari
Managing Partner
HealthXCapital

Tuesday, March 22, 3 PM EDT

Seed Funds

Investing in the Earliest Stage Companies

Andy Merken
Partner & Co-Chair, Life Sciences
Burns & Levinson
(Moderator)		 Dipty Desai, PhD
Co-Chair, TiE Global Health
TiE Angels		 Matt Martin, PhD, MBA
Venture Partner
Pathway Bioventures
Gita Reinitz
Principal (NFX Bio)
NFX

Tuesday, March 22, 4 PM EDT

Tales from the Road: AI Innovators on their Fundraising Journey

Chelsea Sumner, PharmD
NALA Healthcare AI Startups Lead
NVIDIA
(Moderator) 		 Davide Vigano
Co-Founder & CEO
Sensoria		 Ramji Srinivasan
Co-Founder & CEO
Teiko.bio 
Himanshu Misra, PhD
CEO
Enliten AI		 Leila Pirhaji, PhD
Founder & CEO
ReviveMed

Wednesday, March 23, 10AM EDT

Mental & Behavioral Health Panel

Investing in Technologies that Help Manage Well-Being

Lana Ghanem, MBA
Managing Director
Hikma Ventures		 Raj Pallapothu
Managing Director
Bio 9 Ventures		 Mayank Taneja, MBA
Director, Venture Investments
OSF Healthcare Ventures
Charlie Hartwell
Operating Partner
Bridge Builders Collaborative

Wednesday, March 23, 11 AM EDT

Age-Tech Devices

Seniors Embrace Innovative Medtech for Better Quality of Life

Lise Pape
Trustee
Future Care Capital		 Rick Robinson
Vice President, Startup Engagement
AARP Innovation Labs		 Clarence Tan, PhD, MBA
Co-Founder
ABBY by GOGOTECH

Wednesday, March 23, 2 PM EDT

Medtech Strategics

Large Corporations Seeking External Innovation in MedTech

David Uffer
Senior Partner
Alira Health Ventures
(Moderator)		 Lana Caron, MBA
Innovation Lead
Philips Health Technology Ventures		 Juan Cueva, PhD, MBA
Director, New Ventures & Early Innovation Partnering
Johnson & Johnson Innovation
Tali Hirsch
Director, Venture Investments
Fresenius Medical Care Ventures

Wednesday, March 23, 3 PM EDT

AI Drug Discovery and Development

How AI is Accelerating Therapeutic Advancement

Rafael Rosengarten, PhD
Co-Founder, Board Director & Executive Committee Member
The Alliance for Artificial Intelligence in Healthcare
(Moderator) 		 Galym Imanbayev, MD, MBA
Partner
Lightspeed Venture Partners 		 Linda Li
Managing Director
Vickers Venture Partners 
Thea Pham, PhD
Associate, Investments
OCV Partners 

Wednesday, March 23, 4 PM EDT

Tales from the Road: Biotech and MedTech Innovators on their Fundraising Journey

Greg Mannix
VP of International Business Development
Life Science Nation
(Moderator)		 Russell McAllister, MBA
CEO
Bold Therapeutics		 Brian Hess, MBA
CEO
RevBio
Alan Lucas
Co-Founder, CEO & Director
Navigation Sciences

Thursday, March 24, 11 AM EDT

Precision Medicine

Improving Outcomes through a Patient-Tailored Approach

David Crean
President & CEO
Coast BioVentures		 Niall Kerrigan
Program Manager
Plug and Play Ventures		 Eric de la Fortelle
Managing Partner
Cathay Capital

Thursday, March 24, 1 PM EDT

Cell & Gene Therapy

The Next Generation of Therapeutic Technologies

Nishta Rao
Managing Director – Life Science
First Republic Bank
(Moderator)		 Cynthia Lavoie
President & Chief Investment Officer
Centre for Commercialization of Regenerative Medicine		 Scott Galasinski
Global Head, Business Development, Licensing & Strategy, Biopharmaceuticals R&D
AstraZeneca
Megan Krench
Director, Investments
Sanofi Ventures		 Yury Kukushkin
Investment Director
JDRF T1D Fund		 Alicia Yin, PhD
Vice President
6 Dimensions Capital

Thursday, March 24, 2 PM EDT

Defining AI Investment

AI-Exclusive Investors Share Their Perspectives

Amit Garg, MBA
Co-Founder & Managing Partner
Tau Ventures
(Moderator) 		 Navid Alipour, JD, MBA
Managing Partner
Analytics Ventures 		 Isabel Fox
General Partner
Outsized Ventures
Gayathri Radhakrishnan, MBA
Senior Director, Venture Capital – AI Fund
Micron Technology 

Thursday, March 24, 4 PM EDT

Tales from the Road: Age-Tech Innovators on their Fundraising Journey

Jackie Marshall-Cyrus
Director
Jackie Marshall-Cyrus & Associates Ltd
(Moderator)		 Char Hu, PhD
Co-Founder & CEO
The Helper Bees		 Meredith Oppenheim
Founder & CEO
Vitality Society
Kyle Rand
Co-Founder & CEO
Rendever

resi-march-2022

Digital RESI March Sponsors

17 Mar

By Antoinette Lowre, Manager of Business Development, LSN

Digital RESI March starts next week, but the team knows that we cannot host five RESI events each year with the support, dedication, and enthusiasm of our sponsors! With their insight and involvement, RESI continues to bring panels, workshops, and the Innovator’s Pitch Challenge to the early-stage startup community to help them fundraise and grow successfully. Get to know the Digital RESI March sponsors and check out their workshops taking place virtually next week!

Title Sponsors
Gold Sponsors
Exhibitors

If you’re looking to get involved in the early-stage startup community and share your brand and mission with the RESI network, view our sponsorship brochure to learn more about sponsorship opportunities at Digital RESI in 2022!

resi-march-2022

Pitch to Investors at Digital RESI June

17 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Last week, we announced Digital RESI March’s Innovator’s Pitch Challenge (IPC) finalists who will be virtually exhibiting their innovative technologies through a dedicated landing page that includes their key marketing collateral and a recorded pitch video. These companies are also assigned to a live Q&A session featuring active investors and industry experts. The investors will ask high-level questions to the participating companies and provide helpful feedback. Not only does this help prepare companies for future investor meetings, but it has also even led to productive follow-up discussions between participating investors and finalists.

We are excited to continue the IPC for our next conference, Digital RESI, June 7-9. We are now taking applications – apply now to take advantage of this unique opportunity to showcase your innovative technology! Accepted finalists can also take advantage of super early bird registration rates and save $300 by April 15!

Digital RESI March will feature this excellent line-up of investor judges:


Richard Anders
Managing Director
Mass Medical Angels
Yael Benvenisti
CEO
Mediterranean Tower Ventures
Chris Church
Manager, Search & Evaluation, CVRM
AstraZeneca

Adrien Clavairoly
Senior Associate
AdBio Partners
David Crean
President & CEO
Coast BioVentures
Adam Dakin
Managing Director
DreamIt Health

Abhinav Dey
Manager, Business Development
GreenFire Bio, LLC
Jacques Farges
Investor
Keiretsu Forum
Sarah Farr
Associate
Genesys Capital

David Fogel
Angel Investor
TiE Angels
Gary Gershony
Partner
BayMed Venture Partners
Tom Gibbs
Director
Debiopharm Innovation Fund

David Gordon
Head of Investments
Longliv Ventures
Jacob Grainger
Ventures Associate & Program Manager
Plug and Play Ventures
Brian Hakim
Director of International Business Development
MedtecX

Lu Han
Partner
Lumira Ventures
Amrita Jain
Investment Professional
LongeVC
Ray Jang
Associate
Primetime Partners

Quentin Langlois
Vice President
H.I.G. BioHealth Partners
Seo Lee
Principal
SV Investment
Matt Martin
Venture Partner
Pathway Bioventures

Petra Meyer
Managing Director – HealthCare Sector Group Lead
Golden Seeds
Jeffrey Moore
President
MP Healthcare Venture Management (MPH)
Liliana Nordbakk
Chair
Band of Angels

Nishta Rao
Managing Director – Life Science
First Republic Bank
Diana Saraceni
Founder, Managing Director
Panakes Partners
Bryan Shao
K4 Deal Screening Committee
Keiretsu Forum

Paras Sharma
Associate
Genesys Capital
Bill Trainor
Co-Founder and Managing Director
Mutual Capital Partners
Bill Tsai
Investment Analyst, Bio Fund
Taiwania Capital

Robert Tucci
Member Director
Texas Halo Fund
Sa’ar Yaniv
Director of Business Development
Fortress Biotech
Anthony Zlaket
Venture Associate
UnityPoint Health Ventures

resi-march-2022

Hot Investor Mandate: Investment Platform with Billions of AUM Invests $10-15M in Advanced Therapeutics, Next-Generation Devices, Diagnostics, Tools, and More

17 Mar

An investment platform with around €4B in assets under management spans both venture and private equity. Since its inception, the firm has completed 200+ investments. The firm’s latest fund, a dedicated healthcare and life science fund, targets venture and growth stage Tech-Enabled Medicine companies operating at the convergence of health, life sciences and technology. Investment sizes can range from $5M (Seed to Series A) to $50M (Crossover), with average initial check sizes expected to be around $10-15M, and a significant portion will be reserved for later rounds. The firm’s sweet spot is in Series B to C companies.

The firm invests globally across Asia, North America, and Europe (including Middle East). The firm is particularly interested in companies that want to expand to other geographic markets and assist companies to scale globally.

The firm will invest in six areas at the convergence of health, life sciences and technology:

  1. Life science tools – tools enabling advanced diagnostics / treatment: automated cell manufacturing & supply chain management for cell therapy, single cell manipulation, multi-omics consumables & reagents
  2. Diagnostics – enable more precise diagnostics, early detection, treatment support: clinical multi-omics, companion Dx, digital imaging / pathology with AI, clinical decision support systems
  3. Clinical trial enablement – finding the right patient and supporting distributed trials: patient subpopulation selection, trial site matching, virtual / decentralized trials, continuous trial monitoring, real world evidence
  4. Advanced Therapeutics – new modalities enabled by new technology: AI-driven drug discovery, cell & gene therapy, gene editing, microbiome, protein modulation, etc.
  5. New care models – changing point of care & virtual treatments: telehealth, digital therapeutics, digital mental health, wearables, chronic disease monitoring solutions
  6. Next-gen devices / materials – implantables enabled by novel materials / miniaturization, connected devices: biopolymers, non-invasive treatments, monitoring, closed loop therapies, robotic surgery, 3D printing

The firm likes to see strong management teams with proven track record and problem-solving skills or outstanding scientific founders.

The company should have innovation with impact, a clear development and regulatory approval pathway, and capital efficiency (defined timeline and budget and prudent approach to valuation). The firm can lead and co-invest depending on the investment opportunity, and seeks board representation when acting as the lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Invests Up to $20M in USA and Canada-Based Companies, Most Interested in Therapeutics & Medical Device Sectors

17 Mar

A private investment firm is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.

The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.

The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: PE Firm Invests Up to $10M in Early to Growth-Stage Therapeutics, Devices, Diagnostics, and Digital Health Companies With India Angle

17 Mar

An India-focused private equity firm makes early-growth investments in several sectors including the life sciences. The firm seeks to invest in Series A or B and generally invest USD 1-10 million per company. The firm  focuses on India-based companies, but it also invests in companies based outside of India as long as they have some presence in India.

In the life sciences, the firm is interested in therapeutics, specialty pharma, medical devices, diagnostics, healthcare IT, and services. The firm prefers products that require relatively shorter clinical trials. For therapeutics, the firm generally invests in products in pre-clinical stage and is indication agnostic, but typically does not consider orphan indications. For medical devices, the firm will consider all classes and generally looks for devices beyond proof-of-concept.

The firm can both lead or act as co-investor in syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm With Ties to Large Health System Invests Up to $20M in Global Medical Device, Diagnostics, Digital Health and Healthcare Services Companies

17 Mar

An investment firm based in USA that manages funds of a large health system looks to invest in companies of strategic interest to its health system investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →